Answers are grounded in this paper and cite their sources.
OBJECTIVES: Teprotumumab is a novel monoclonal antibody treatment for thyroid eye disease that acts through IGF-1R inhibition. A subset of patients has been reported to experience varying levels of hearing change and other otologic symptoms after therapy. This study aimed to investigate auditory changes following monoclonal antibody IGF-1R inhibitor treatment in mice. METHODS: Adult CBA/CaJ mice were treated with varying doses of a chimeric IGF-1R monoclonal antibody (cIGF-1R mAb), saline, or IgG2a isotype controls (n = 10 per group) weekly for 20 weeks. Mice underwent auditory brainstem response (ABR) and distortion product otoacoustic emission (DPOAE) testing at regular intervals. Suprathreshold ABR Wave 1 amplitude growth functions were analyzed at the final timepoint, along with histological assessment of auditory hair cells and presynaptic ribbons. Bodyweight, exposure of cIGF-1R mAb, and the inhibitory effect of cIGF-1R mAb in lung tissues were also assessed. RESULTS: At 20 weeks, there was no significant increase in ABR or DPOAE threshold shift of the experimental cIGF-1R mAb groups compared with saline controls. No significant decrease in hair cell and presynaptic ribbon counts or suprathreshold ABR Wave 1 amplitude growth functions were observed amongst cIGF-1R mAb-treated subjects compared with saline controls. Inhibitory activity of cIGF-1R mAb was confirmed by the reduced bodyweight gain compared with controls and sustained IGF-1R pathway inhibition over the study period. CONCLUSION: IGF-1R inhibition in mice shows no consistent electrophysiologic or histological effect on auditory function. Further animal and clinical studies are warranted to evaluate a potential association between IGF-1R treatment and hearing loss. LEVEL OF EVIDENCE: N/A.
No takes yet. Share an insight, caveat, or question.
Ward et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: